Silexion Therapeutics Corp
SLXN
$3.78
$0.051.34%
NASDAQ
12/31/2024 | 09/30/2024 | 03/31/2024 | |||
---|---|---|---|---|---|
Revenue | -- | -- | -- | ||
Total Other Revenue | -- | -- | -- | ||
Total Revenue | -- | -- | -- | ||
Cost of Revenue | -- | -- | -- | ||
Gross Profit | -- | -- | -- | ||
SG&A Expenses | 746.31% | -2,358.67% | 127.56% | ||
Depreciation & Amortization | -- | -- | -- | ||
Other Operating Expenses | -- | -- | -- | ||
Total Operating Expenses | 204.45% | -999.32% | 54.70% | ||
Operating Income | -204.45% | 999.32% | -54.70% | ||
Income Before Tax | -268.86% | 1,376.71% | -93.45% | ||
Income Tax Expenses | -67.24% | 66.67% | -50.00% | ||
Earnings from Continuing Operations | -266.58% | 1,366.01% | -91.52% | ||
Earnings from Discontinued Operations | -- | -- | -- | ||
Extraordinary Item & Accounting Change | -- | -- | -- | ||
Minority Interest in Earnings | -60.00% | 59.09% | 261.29% | ||
Net Income | -281.79% | 1,405.84% | -77.39% | ||
EBIT | -204.45% | 999.32% | -54.70% | ||
EBITDA | -204.61% | 987.45% | -56.62% | ||
EPS Basic | -- | -- | -- | ||
Normalized Basic EPS | -- | -- | -- | ||
EPS Diluted | -- | -- | -- | ||
Normalized Diluted EPS | -- | -- | -- | ||
Average Basic Shares Outstanding | -- | -- | -- | ||
Average Diluted Shares Outstanding | -- | -- | -- | ||
Dividend Per Share | -- | -- | -- | ||
Payout Ratio | -- | -- | -- |